

8-20-04

JFW

Express Mail Label No.: EV 392131246 US

Date of Deposit: August 19, 2004

Attorney Docket No. 26448-520



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANTS: Reinhard, et al.

SERIAL NUMBER: 10/824,848

EXAMINER: Not Yet Assigned

FILING DATE: April 15, 2004

ART UNIT: 1614

FOR: DIHYDROTHIAZINE PRODRUGS OF THIAZOLIUM AGENTS

Mail Stop Amendment

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Pursuant to the duty of disclosure under 37 C.F.R. §§1.56, 1.97 and 1.98, Applicants hereby make of record the documents listed on the attached modified Form PTO-1449. The order of presentation of the references should not be construed as an indication of the importance of the references.

This Supplemental Information Disclosure Statement is being filed before the mailing date of a first Office Action on the merits in the above-identified case. Accordingly, no fee or certification is believed required.

It is respectfully requested that the Examiner consider completely the cited information, along with any other information, in reaching a determination concerning the patentability of the present claims, and sign the enclosed form PTO-1449 to evidence that the cited information has been fully considered by the Patent and Trademark Office during the examination of this application.

By submitting this Supplemental Information Disclosure Statement, the Applicants make no representation that: (1) a search has been performed, of the extent of any search performed, or that more relevant information does not exist; (2) the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 C.F.R. §1.56(b); and (3) the information cited in the Statement is, or is considered to be, in fact, prior art as defined by 35 U.S.C. §102.

APPLICANTS: Reinhard, et al.
U.S.S.N.: 10/824,848

Notwithstanding any statements by the Applicants, the Examiner is urged to form his/her own conclusion regarding the relevance of the cited information. An early and favorable action is hereby requested.

Please charge any fees that may be due, or credit any overpayment of same, to Deposit Account No. 50-0311, Reference No. 26448-520.

Respectfully submitted,



Ivor R. Elrifi, Reg. No. 39,529
Heidi A. Erlacher, Reg. No. 45,409
Attorney(s) for Applicants
MINTZ, LEVIN, COHN, FERRIS,
GLOVSKY and POPEO, P.C.
Address all written correspondence to
Customer no.: 30623
Tel: (617) 542-6000
Fax: (617) 542-2241

Date: August 19, 2004

TRA 1950022v1

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANTS: Reinhard, et al.

SERIAL NUMBER: 10/824,848

EXAMINER: Not Yet Assigned

FILING DATE: April 15, 2004

ART UNIT: 1614

FOR: DIHYDROTHIAZINE PRODRUGS OF THIAZOLIUM AGENTS

Mail Stop Amendment

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

TRANSMITTAL LETTER


Transmitted herewith for filing in the present application are the following documents:

1. Supplemental Information Disclosure Statement (2 pages);
2. Modified Form 1449/PTO (3 pages), in duplicate;
3. Cited References A6-17; B1-10; C1-51; and
4. Return Postcard.

If the enclosed papers are considered incomplete, the Mail Room and/or the Application Branch is respectfully requested to contact the undersigned at (617) 542-6000, Boston, Massachusetts.

The Commissioner is authorized to charge any fees that may be due, or to credit any overpayment, to the undersigned's account, Deposit Account No. 50-0311 Ref. No. 26448-520. A duplicate copy of this transmittal letter is enclosed herewith.

Respectfully submitted,



Ivor R. Elrifi, Reg. No. 39,529

Heidi A. Erlacher, Reg. No. 45,409

Attorney(s) for Applicants

MINTZ, LEVIN, COHN, FERRIS,

GLOVSKY and POPEO, P.C.

Address all written correspondence to

Customer no.: 30623

Tel: (617) 542-6000

Fax: (617) 542-2241

Date: August 19, 2004

Please type a plus sign (+) in this box



**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Application Number	10/824,848
Filing Date	April 15, 2004
First Named Inventor	Reinhard
Group Art Unit	1614
Examiner Name	Not Yet Assigned
Attorney Docket Number	26448-520

U.S. PATENT DOCUMENTS

Exam Initials	Cite No.	U.S. Patent Document No.	Issue Date	Name of Patentee(s) or Applicant(s)	Class	Sub Class	Filing Date If Appropriate
	A6	4,609,970	09/02/86	Hilpert	361	399	
	A7	4,683,312	07/28/87	Dominianni, et al.	548	341	
	A8	4,758,583	07/19/88	Cerami, et al.	514	399	
	A9	5,108,930	04/28/92	Ulrich, et al.	436	111	
	A10	5,230,998	07/27/93	Neurath, et al.	435	7.1	
	A11	5,262,152	11/16/93	Ulrich, et al.	424	54	
	A12	5,366,885	11/22/94	Barranco, III et al.	435	6	
	A13	5,656,261	08/12/97	Cerami, et al.	424	53	
	A14	5,850,840	12/22/98	Cerami, et al.	131	330	
	A15	5,854,000	12/29/98	Bucala, et al.	435	7.1	
	A16	6,007,865	12/28/99	Cerami, et al.	426	656	
	A17	6,121,300	09/19/00	Wagle, et al.	514	365	

U.S. PUBLISHED APPLICATION DOCUMENTS

Exam Initials	Cite No.	U.S. Published Application No.	Published Date	Name of Patentee(s) or Applicant(s)	Class	Sub Class	Filing Date If Appropriate

FOREIGN PATENT DOCUMENTS

Exam Initials	Cite No.	Foreign Patent Document Office Number	Name of Patentee(s) or Applicant(s)	Date of Publication	Translation Yes No
	B1	EP 0 167 139 A1	MERCK & CO. INC.	01/08/86	
	B2	EP 0 170 037 A2	ZÜNDWARENFABRIK STARCKE GMBH & CO.	02/05/86	x
	B3	EP 0 364 344 A2	MERRELL DOW PHARMACEUTICALS INC.	04/18/90	
	B4	EP 0 586 806 A1	CASSELLA AKTIENGESSELLSCHAFT	03/16/94	X
	B5	EP 0 614 886 A1	DRUG DELIVERY SYSTEM INST., LTD	09/14/94	
	B6	DT 2 323 465	SOC. D'ETUDES PROD. CHIMIQUES	11/22/73	X
	B7	JP 1-143855	MITSUI PETROCHEM. IND. LTD.	06/06/89	X
	B8	JP 60-184038	NIHON KASEI KK	09/19/85	X
	B9	WO 94/11490	THE ROCKEFELLER UNIVERSITY	05/26/94	
	B10	WO 94/20083	THE PICOWER INSTITUTE FOR MEDICAL RESEARCH	09/15/94	

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.
	C1	Adam, et al., <i>Tetrahedron Lett.</i> , 36:3063-3066 (1969).
	C2	Archer, et al., <i>J. Med. Chem.</i> , 22(3):306-309 (1979).
	C3	Asif, et al., <i>Proc. Natl. Acad. Sci. USA</i> , 97(6):2809-2813 (2000).
	C4	Brown, R.D., <i>J. Theor. Biol.</i> , 143:565-573 (1990).

C5	Brownlee, et al., <i>Diabetes</i> , (Suppl 1) 42A, Abstract 166 (1986).
C6	Brownlee, et al., <i>Science</i> , 232:1629-1632 (1986).
C7	Bucala, et al., <i>Advances in Pharmacol.</i> , Academic Press, 23:1-34 (1992).
C8	Chang et al., <i>J. Biol. Chem.</i> , 260(13):7970-7974 (1985).
C9	Crosby, et al., <i>J. Am. Chem. Soc.</i> , 92(9):2891-2900 (1970).
C10	Dominiani, et al., <i>J. Med. Chem.</i> , 32:2301-2306 (1989).
C11	Eble, et al., <i>J. Biol. Chem.</i> , 258(15):9406-9412 (1983).
C12	Galera, et al., <i>J. Heterocyclic Chem.</i> , 23:1889-1892 (1986).
C13	Gandasegui, et al., <i>Heterocycles</i> , 31:1801-1809 (1990).
C14	Hayase, et al., <i>J. Biol. Chem.</i> , 263(7):3758-3764 (1989).
C15	Hopmann, R.F.W., <i>Ann. N.Y. Acad. Sci.</i> , <u>Alkali-Induced Transformations</u> , pgs. 32-50 (1982).
C16	Inoge, et al., <i>J.C.S. Chem. Comm.</i> , 12:549-550 (1980).
C17	Kass, et al., <i>Circulation</i> , 104:r8-r14 (2001).
C18	Kawakishi et al., <i>Maillard Reactions Chem. Food Health.</i> , 151:281-285 (1994).
C19	Kibirev, et al., <i>Ukrainian Journal of Chemistry</i> , 30(5):488-495 (1964) (English Translation provided).
C20	Kluger, et al., <i>J. Am. Chem. Soc.</i> , 103(4):884-888 (1981).
C21	Makita, et al., <i>J. Biol. Chem.</i> , 267(8):5133-5138 (1992).
C22	Marcaccini, et al., <i>Tetrahedron Lett.</i> , 43:8591-8593 (2002).
C23	Mizuhara, et al., <i>J. Am. Chem. Soc.</i> , 76:571-573 (1954).
C24	Monn, et al., <i>J. Org. Chem.</i> , 59:2773-2778 (1994).
C25	Nicholls, et al., <i>Lab. Invest.</i> , 60(4):486-491 (1989).
C26	Nordbo, H., <i>J. Dent. Res.</i> , 58(4):1429 (1979).
C27	Oimomi, et al., <i>Agric. Biol. Chem.</i> , 53(6):1727-1728 (1989).
C28	Oimomi, et al., <i>Diabetes Res. Clin. Pract.</i> , 6(4):311-313 (1989).
C29	Pongor, et al., <i>Proc. Natl. Acad. Sci. USA</i> , 81:2684-2688 (1984).
C30	Potts, et al., <i>J. Org. Chem.</i> , 41(2):187-191 (1976).
C31	Potts, et al., <i>J. Org. Chem.</i> , 42(9):1648-1649 (1977).
C32	Schoenafinger, et al., <i>Chem. Abstracts</i> , Abstract No. 173495q , 120:682 (1994).
C33	Sell, et al., <i>J. Biol. Chem.</i> , 264(36):21597-21602 (1989).
C34	Sheehan, et al., <i>J. Org. Chem.</i> , 39(9):1196-1199 (1974).
C35	Singh, et al., <i>Tetrahedron</i> , 48(22):4545-4550 (1992).
C36	Sohda, et al., <i>Chem. Abstracts</i> , Abstract No. 132169y , 113:652 (1990).
C37	Sohda, et al., <i>Chem. Abstracts</i> , Abstract No. 191334w , 113:723 (1990).
C38	Tagaki, et al., <i>Bull. Chem. Soc. Jpn.</i> , 53(2):478-480 (1980).
C39	Takamizawa, et al., <i>J. Org. Chem.</i> , 33(11):4038-4045 (1968).
C40	Takamizawa, et al., <i>Tetrahedron Lett.</i> , 37:4027-4030 (1968).
C41	Tamura, et al., <i>Synthesis</i> , 1:1-17 (1977).
C42	Thornalley, et al., <i>Biochem. Pharmacol.</i> , 57:303-307 (1999).
C43	Tsuge, et al., <i>Chem. Lett.</i> , 5:711-714 (1982).
C44	Ulrich, et al., <i>Modem Aging Res.</i> , 7:83-92 (1985).
C45	Voller, et al., <i>Alternative Immunoassays</i> , Chapter 6, ppg.77-86 (1985).

C46	Vovk, et al., <i>Ukrainian Journal of Chemistry</i> , 51:521-525 (1985).
C47	Washabaugh, et al., <i>Bioorganic Chem.</i> , 20:296-312 (1992).
C48	Wolffenbuttel, et al., <i>Proc. Natl. Acad. Sci. USA</i> , 95:4630-4634 (1998).
C49	Yamazaki, et al., <i>Chem. Pharm. Bull.</i> , 40(4):1025-1028 (1992).
C50	Yang, et al., <i>Arch. Biochem. Biophys.</i> , 412:42-46 (2003).
C51	Yoshimura, et al., <i>Chem. Abstracts, Abstract No. 15815y</i> , 118:12 (1993).

* a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. _____, filed _____, and relied upon for an earlier filing date under 35 U.S.C. §120 (continuation, continuation-in-part, and divisional applications).

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered.

Include copy of this form with next communication to applicant.

TRA 1943212v1